-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
-
UCLA's Scooter Jackson named Week 11 Lott IMPACT Trophy Player of the Week
-
Paris Hilton Guides Loti as Chief Advocacy Officer to Put Digital Identity Protection in Everyone's Hands
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
Trump May Reclassify Marijuana - MMJ BioPharma To Escape The DEA's Seven Year Cannabis Trial Roadblock?
Trump said his administration will focus on research to unlock the medical uses of marijuana, and other priorities the marijuana industry has sought. However, will employees within the DEA continue trying to block President Trumps marijuana orders?
WASHINGTON, DC / ACCESS Newswire / August 11, 2025 / President Donald J. Trump is thinking about moving marijuana to a lower drug classification, according to the Wall Street Journal and other reports. If he does, it will finally crack open the door for companies like MMJ BioPharma Cultivation- and for patients who have been waiting far too long for real, FDA-approved cannabis medicines.

At a recent private fundraiser, Trump said he was looking at reclassifying marijuana from Schedule I - the same category as heroin - to Schedule III. This wouldn't make marijuana completely legal, but it would make a huge difference. It would loosen strict federal rules, open the door for more research, and let legitimate companies like MMJ BioPharma deduct normal business expenses. It could also speed up FDA clinical trials for new medicines.
For MMJ BioPharma, this change would be nothing short of a lifeline. "Over the past seven years, we've poured millions of dollars into doing everything by the book", stated Duane Boise CEO.
Filing FDA Investigational New Drug (IND) applications
Earning orphan drug designations for Huntington's disease and multiple sclerosis
Building Good Manufacturing Practice (GMP) facilities
Creating strict quality control protocols
Even developing a soft gelatin cannabis capsule ready for human testing in FDA-approved clinical trials
Seven Years, DEA No Action
Back in 2018, MMJ applied for a DEA license to grow pharmaceutical-grade cannabis for our FDA-approved research. That's the one piece we can't do without. And yet, after seven years, we're still waiting.
We've met every legal requirement. We've passed every inspection. We've followed every rule. But the DEA has refused to move forward.
This isn't just frustrating - it's directly against the Medical Marijuana and Cannabidiol Research Expansion Act, a law Congress passed in 2022 to speed up approvals for legitimate cannabis research. Instead of following the law, the DEA has buried our application in bureaucracy. Meanwhile, patients are left empty handed.
How Trump Could Break the Deadlock
When Trump reclassifies marijuana to Schedule III, it will tear down the DEA's most restrictive barriers to research. That would allow companies like ours to:
Get the cannabis material we need for FDA trials without endless delays
Test new formulations and delivery methods for patients with serious diseases
Provide safe, standardized, federally approved medicine instead of leaving patients to rely on unregulated products
The Stakes Are Personal
While the DEA drags its feet, Trump is looking at issues that unite most Americans - the so-called "80-20 issues" that have wide support. Medical cannabis is one of them. Nearly everyone agrees that if a medicine can be proven safe and effective, patients should have access to it.
For MMJ BioPharma, the past seven years have been a master class in patience - and pain. We've built the labs, hired the scientists, perfected the medicine, and followed the rules to the letter. Yet we've been stuck in limbo because one agency won't do its job.
When Trump acts, it could finally end the waiting game. It would be a win for science, a win for patients, and a win for every company that plays by the rules.
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-8583
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire
D.Lopez--AT